Biomarin Pharmaceutical (BMRN) Operating Income: 2009-2025
Historic Operating Income for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$46.7 million.
- Biomarin Pharmaceutical's Operating Income fell 141.00% to -$46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 75.81%. This contributed to the annual value of $484.2 million for FY2024, which is 160.65% up from last year.
- Biomarin Pharmaceutical's Operating Income amounted to -$46.7 million in Q3 2025, which was down 116.86% from $276.9 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Operating Income registered a high of $276.9 million during Q2 2025, and its lowest value of -$65.9 million during Q4 2021.
- In the last 3 years, Biomarin Pharmaceutical's Operating Income had a median value of $88.5 million in 2024 and averaged $102.2 million.
- In the last 5 years, Biomarin Pharmaceutical's Operating Income soared by 1,362.93% in 2023 and then plummeted by 141.00% in 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Operating Income (Quarterly) stood at -$65.9 million in 2021, then skyrocketed by 80.13% to -$13.1 million in 2022, then surged by 308.43% to $27.3 million in 2023, then soared by 491.69% to $161.4 million in 2024, then slumped by 141.00% to -$46.7 million in 2025.
- Its Operating Income stands at -$46.7 million for Q3 2025, versus $276.9 million for Q2 2025 and $223.9 million for Q1 2025.